- Disease: Acute SARS-CoV-2
- Study type: Observational Cohort Study
- Study type descriptors: Prospective, Single centre
- Study aim: To evaluate the effectiveness and safety of remdesivir and SARS-CoV-2 monoclonal antibodies in preventing COVID-19 progression in patients with hematological malignancies and mild-to-moderate disease in real clinical practice
- Number of participants enrolled: 55
- Study enrolling from to
- Study includes follow-up for 5.5 months
Study Data
- Adults
- Elderly
- Fragile population
- Immunocompromised host
- Hospital wide
- SARS-CoV-2
- Acute SARS-CoV-2
- Pharmacological intervention
- Antivirals
- Remdesivir
External Links
Other information
If you would like to contact the Principal Investigator of the study please email: ccb@ateneo.univr.it
The data is updated up to